SYDNEY--(BUSINESS WIRE)--Tyrian Diagnostics Limited (ASX:TDX) announced today that Tyrian and BD (Becton, Dickinson and Company) have entered an extended option period under their current agreement. The extension will allow further feasibility studies of the suitability of Tyrian’s proprietary tuberculosis (TB) protein markers for the development of rapid diagnostic tests to detect active TB disease.
